Nearly 300,000 women in England will be offered a preventative pill to help them avoid breast cancer. The drug, anastrozole, has been available for years as a breast cancer treatment, and had ...

In the efficacy study, the patients with advanced breast cancer received anastrozole 0.5 or 1 mg/day for 12 weeks or more and tumour response was determined at 4-week intervals during treatment.

Overall, there were no significant differences between anastrozole and placebo groups ... with only a few controlling for prior chemotherapy treatment. One repeatedly cited cross-sectional pilot ...

De Lima submitted extensive medical documentation confirming a medical condition which necessitated the prescribed treatment of anastrozole. Anastrozole was clearly listed on the label's listed ...

Anastrozole treatment continued for 36 months or until completion of linear growth. Of the 52 patients recruited, 50, 41 and 28 completed 12 months, 24 months and 36 months of treatment ...

plus an aromatase inhibitor (anastrozole or letrozole) as their first-line treatment for advanced disease. When the study ...

This study reveals that Fe-doped boron nitride nanoparticles improve Anastrozole delivery, offering enhanced stability and targeted therapy for breast cancer.

Anastrozole was first recommended as a preventive option by the National Institute for Health and Care Excellence (Nice) in 2017, however, with the treatment being unlicensed in this use ...